Pacira BioSciences, Inc.
NASDAQ:PCRXDrug Manufacturers - Specialty & Generic
-$0.18 today
- Market cap
- $1.46B
- Beta
- 0.29
- P/E (TTM)
- 176.9
- EPS (TTM)
- $0.13
Volume 1.81M
Average 0.57M
PCRX Sales of Investments
Cash received from selling or redeeming investments.
Pacira BioSciences, Inc.NASDAQ: PCRX
Sales of Investments · Q1 FY2026 · quarter ended Mar 2026
Sales of investments dips below year-ago levels
Q1 FY2026 sales of investments of $22.5M fell 67.5% year over year, behind the +8.1% change in trailing-twelve-month sales of investments. Sequentially, it fell 46.7% from the prior quarter. Over 3 fiscal years it compounded at +4.2% a year.
Context
- Sales of investments amounted to 37.0% of revenue in FY2025, up 11.4 pp from a year earlier.
- Sales of investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -67.5% toward the trailing-twelve-month pace of +8.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Sales of Investments history
USD · from the cash flow
- Latest · FY2025
- 268.88M USD
- Year-over-year change
- +49.7%
- 4-year CAGR
- -29.3%
| Period | Period end | Sales of Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 268.88M | +49.7% |
| FY2024 | 2024-12-31 | 179.57M | -24.3% |
| FY2023 | 2023-12-31 | 237.07M | -0.2% |
| FY2022 | 2022-12-31 | 237.58M | -78.0% |
| FY2021 | 2021-12-31 | 1.08B | — |
Sales of Investments vs competitors
How PCRX compares with its peers on the latest reported figures
- PCRX's LTM Mar 2026 sales of investments of $222.13M is the 2nd largest of the 4 companies compared; the peer median is $68.17M.
- Its year-over-year change of +8.1% is the 2nd highest of 3, against a peer median of +62.9%.
- Sales of investments amounts to 30.2% of revenue for PCRX, versus a peer median of 126.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.36B | +148.4% | +59.6% | 163.8% | |
| LTM Mar 2026 | $222.13M | +8.1% | +4.2% | 30.2% | |
| LTM Mar 2026 | $68.17M | -22.6% | — | 8.6% | |
| LTM Mar 2026 | $42.87M | — | — | 126.6% | |
LTGOLatigo Biotherapeutics Inc. | — | — | — | — | — |
| Peer median (excluding PCRX) | $68.17M | +62.9% | +59.6% | 126.6% | |
Competitors are the stored peer set for PCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 41.98M | 15.91M | 41.96M | (99.56M) | 7.03M |
| Depreciation & Amortization | 28.55M | 91.5M | 75.57M | 78.79M | 91.02M |
| Deferred Income Tax | 10.87M | (7.95M) | 15.62M | 20.62M | 6.48M |
| Stock-Based Compensation | 42.25M | 48.09M | 47.9M | 51.17M | 57.5M |
| Change in Working Capital | (18.67M) | (16.43M) | (45.78M) | (18.52M) | (38.27M) |
| Accounts Receivables | (10.43M) | (2.08M) | (7.16M) | (7.75M) | (10.74M) |
| Inventory | (4.47M) | 2.49M | (8.29M) | (20.93M) | (27.57M) |
| Accounts Payables | (10.26M) | 6.27M | 916K | 3.08M | (5.6M) |
| Other Working Capital | 6.49M | (23.11M) | (31.24M) | 7.07M | 5.64M |
| Other Non-Cash Items | 20.75M | 14.15M | 19.39M | 156.89M | 28.22M |
| Operating Cash Flow | 125.72M | 145.27M | 154.65M | 189.39M | 151.99M |
| Capital Expenditures | (45.87M) | (30.08M) | (15.16M) | (10.64M) | (15.33M) |
| Acquisitions (Net) | (420.04M) | 0 | 0 | 0 | (16.7M) |
| Purchases of Investments | (628.68M) | (400.69M) | (144.37M) | (252.21M) | (142.29M) |
| Sales of Investments | 1.08B | 237.58M | 237.07M | 179.57M | 268.88M |
| Other Investing Activities | (4M) | (32M) | 0 | 0 | 4.93M |
| Investing Cash Flow | (20.79M) | (225.19M) | 77.54M | (83.28M) | 99.48M |
| Debt Repayment | 363.75M | (427.69M) | (180.76M) | 76.62M | (218.99M) |
| Common Stock Issued | 26.66M | 27.34M | 0 | 0 | 3.3M |
| Common Stock Repurchased | 0 | 0 | (106K) | (25M) | (148.33M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.71M) | (1.18M) | (2.16M) | (34.25M) | (5.62M) |
| Financing Cash Flow | 380.69M | (401.53M) | (183.03M) | 17.36M | (369.63M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (77K) |
| Net Change in Cash | 485.62M | (481.44M) | 49.16M | 123.48M | (118.23M) |
| Free Cash Flow | 79.85M | 115.2M | 139.49M | 178.75M | 136.66M |
Pacira BioSciences, Inc.
NASDAQ:PCRX
Intrinsic Alpha fair value
Locked
Current Price
$36.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.